....under the umbrella of a bigger drug co., i assume the drug approval process would accelerate, thus reducing timing risk (vis a vis competitors) ...i think, if sarepta has received interest, they need to entertain it seriously, lest the co.'s board has breached its fiduciary duty
Clark, I have to agree. I don't claim to be an expert on all this, but it's hard to shake the feeling that someone with big guns in terms of clout and money could have made this AA thing work without a hitch. I'm not faulting CG for his effort, or even his ambition...but if he really believes it's important to get this drug out as soon as possible for the kids, then maybe it's time to hand the ball off to a bigger player.
they have been adamant from the day CG was hired that they will remain independent. there is little doubt it would fetch 2-3B in a sale today and 5B once approved. board owns little stock so they could care less and CG wants to build an empire.